Heteroaryl compounds which inhibit leukocyte adhesion mediated by α4 integrins
US7335663B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 27, 2003 |
| Grant date | Feb 26, 2008 |
| Priority date | — |
| Expiry date | Jul 20, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds which bind α4 integrins, where the α4 integrin is preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by α4 integrins, where the α4 integrin is preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.